Iterion Therapeutics' lead product, Tegavivint, is a potent and selective inhibitor of nuclear β-catenin,a historically “undruggable” oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Many large pharmaceutical companies have tried and failed to develop drugs that are able to effectively bind the protein. The differentiating aspect of Tegavivint is that it does not bind β-catenin directly. Rather, it associates with TBL1 (Transducin Beta-like Protein One), a protein that β-catenin must engage to promote cancer gene expression.